answer text |
<p>Departmental officials have had a number of discussions with colleagues in the
National Institute for Health and Care Excellence (NICE) to enquire about progress
of the ongoing appraisal of nusinersen (Spinraza) for the treatment of spinal muscular
atrophy. Discussions between NHS England, NICE and Biogen (the company that manufactures
nusinersen) are ongoing to seek to agree a commercial agreement that would enable
NICE to recommend use of nusinersen as a clinically and cost effective use of National
Health Service resources.</p>
|
|